Adult and juvenile dermatomyositis treatment.
corticosteroids
dermatomyositis
immunosuppressants
malignancy
management
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
17
08
2022
received:
21
06
2022
accepted:
02
09
2022
pubmed:
7
9
2022
medline:
14
2
2023
entrez:
6
9
2022
Statut:
ppublish
Résumé
Dermatomyositis is a rare autoimmune inflammatory condition affecting skin and muscles. The disease can be seen in both adults and children. It can be associated with malignancy. Considering involvement of skin in the disease, many patients consult dermatologists for its treatment. Hence, knowledge about its presentation, complications, prognosis, and treatment is necessary. The objective of this review article is to provide comprehensive information about treatment of dermatomyositis. In this review article, we reviewed the published literature on adult and juvenile dermatomyositis to highlight the treatment. Articles published in peer-reviewed journals including reviews, clinical trials, case series, and case reports published in electronic database (MEDLINE/PubMed) through January 2021, cross references of respective articles and trials from clinicaltrials.gov were included for qualitative analysis of the literature. Treatment options for dermatomyositis include traditional immunosuppressive agents and immunomodulatory therapy. High-dose corticosteroids represent the first line of treatment while other immunosuppressive agents are also used, either in combination with or as an alternative to corticosteroids, after initial treatment failure. Some biological agents have been used for the treatment of dermatomyositis with variable responses. Although several treatment options are available, several questions remain unanswered about the optimal treatment of dermatomyositis.
Substances chimiques
Immunosuppressive Agents
0
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-401Informations de copyright
© 2022 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Références
Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018;28:913-921.
Isak V, Jorizzo JL. Recent developments on treatment strategies and the prognosis of dermatomyositis: a review. J Dermatolog Treat. 2018;29:450-459.
Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21:339-353.
Anic B, Cerovec M. Polymyositis/dermatomyositis - clinical picture and treatment. Reumatizam. 2012;59:44-50.
Shinjo SK, Sallum AME, Oba-Shinjo SM, Silva MG, Silva CA, Maire SKN. Comparison between treatment naive juvenile and adult dermatomyositis muscle biopsies: difference of inflammatory cells phenotyping. Adv Rheumatol. 2018;58:37. doi:10.1186/s42358-018-0037-5
Sun C, Lee J-H, Yang Y-H, et al. Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol. 2015;56:31-39.
Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7:664-675.
Callander J, Robson Y, Ingram J, Piguet V. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. Br J Dermatol. 2018;179:1248-1255.
Shinjo SK, de Souza FHC. Update on the treatment of calcinosis in dermatomyositis. Rev Bras Rheumatol. 2013;53:211-214.
Hirai T, Ikeda K, Tsushima H, et al. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen. 2018;38:1. doi:10.1186/s41232-017-0058-1
Zerdes I, Tolia M, Nikolaou M, et al. How can we effectively address the paraneoplastic dermatomyositis: diagnosis, risk factors and treatment options. J BUON. 2017;22:1073-1080.
Marsol IB. Dermatomyositis. Reumatol Clin. 2009;5:216-222.
Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82:283-296.
Gordon PA, Winer JB, Hoogendijk JE, Choy EHS. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;2012(8):CD003643.
Hornig J, Weinhage T, Schmidt LH, et al. Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z Rheumatol. 2018;77:952-957.
Castano-Amores C, Nieto-Gomez P. Cerebral toxoplasmosis associated with treatment with rituximab, azathioprine and prednisone for dermatomyositis. Br J Clin Pharmacol. 2020;87:1525-1528. doi:10.1111/bcp.14445
Choy EHS, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology. 2002;41:7-13.
Stager K, Wise L. MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin. BMJ Case Rep. 2020;13:e236431. doi:10.1136/bcr-2020-236431
Danieli MG, Gambini S, Pettinari L, Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev. 2014;13:1048-1054.
Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-324.
Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology. 2017;56:247-254.
Fiehn C, Unger L, Schulze-Koops H, et al. Rituximab for the treatment of poly- and dermatomyositis: results from the GRAID-2 registry. Z Rheumatol. 2018;77:40-45.
Tjarnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;17:55-62.
Tang Q, Ramskold D, Krystufkova O, et al. Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis. Scand J Immunol. 2019;89:e12732.
Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib - a report of two cases. J Autoimmun. 2019;100:131-136.
Kato M, Ikeda K, Kageyama T, et al. Successful treatment for refractory interstitial lung disease and pneumomediastinum with multidisciplinary therapy including tofacitinib in a patient with anti-MDA5 antibody-positive dermatomyositis. J Clin Rheumatol. 2019;27:S574-S577. doi:10.1097/RHU.0000000000000984
Navarro-Navarro I, Jimenez-Gallo D, Rodriguez-Mateos ME, Rodriguez-Hernandez C, Linares-Barrios M. Treatment of refractory anti-NXP2 and anti-TIF1γ dermatomyositis with tofacitinib. J Dtsch Dermatol Ges. 2020;19:443-447. doi:10.1111/ddg.14276
Kurtzman DJB, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152:944-945.
Schiffenbauer A, Garg M, Castro C, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2018;47:858-864.
Bitar C, Maghfour J, Ho-Pham H, Stumpf B, Boh E. Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case Rep. 2019;5:191-194.
Charlton D, Moghadam-Kia S, Smith K, Aggarwal R, English JC 3rd, Oddis CV. Refractory cutaneous dermatomyositis with severe scalp pruritus responsive to apremilast. J Clin Rheumatol. 2019;27:S561-S562. doi:10.1097/RHU.0000000000000999
Ho-Mahler N, Turner B, Eaddy M, Hanke ML, Nelson WW. Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/polymyositis. Open Access Rheumatol. 2020;12:21-28.
Fioranelli M, Roccia MG, Lotti T. Treatment of dermatomyositis with ruxolitinib. Dermatol Ther. 2016;29:285.
Kawasumi H, Gono T, Kawaguchi Y, et al. Clinical manifestations and myositis-specific autoantibodies associated with physical dysfunction after treatment in polymyositis and dermatomyositis: an observational study of physical dysfunction with myositis in Japan. Biomed Res Int. 2016;2016:9163201. doi:10.1155/2016/9163201
Pandya JM, Loell I, Hossain MS, et al. Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. Arthritis Res Ther. 2016;18:80. doi:10.1186/s13075-016-0974-5
Manudhane AP, Schrom KP, Ezaldein HH, Armile JA. Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis. Dermatol Online J. 2019;35:13030/qt89b75552.
Groh M, Rogowska K, Monsarrat O, Denoel A, Blanche P, Guillevin L. Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy. Clin Exp Rheumatol. 2015;33:904-905.
Wu J-Q, Lu M-P, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2020;16:31-43.
Huber AM, Kim S, Reed AM, et al. Childhood arthritis and rheumatology research Alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44:110-116.
Neto NSR, Goldenstein-Schainberg C. Juvenile dermatomyositis: review and update of the pathogenesis and treatment. Rev Bras Rheumatol. 2010;50:299-312.
Kim S, Kahn P, Robinson AB, et al. Childhood arthritis and rheumatology research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15:1. doi:10.1186/s12969-016-0134-0
Papadopoulou C, Wedderburn LR. Treatment of juvenile dermatomyositis: an update. Paediatr Drugs. 2017;19:423-434.
Liu K, Tomlinson G, Reed AM, et al. Pilot study of the juvenile dermatomyositis consensus treatment plans: a CARRA registry study. J Rheumatol. 2021;48:114-122.
Deakin CT, Campanilho-Marques R, Simou S, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. Arthritis Rheumatol. 2018;70:785-793.
Spencer CH, Rouster-Stevens K, Gewanter H, et al. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the childhood arthritis and rheumatology research Alliance in North America. Pediatr Rheumatol Online J. 2017;15:50.
Montoya CL, Gonzalez M, Ospina FE, Tobon GJ. A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab. J Clin Rheumatol. 2017;23:129-130.
Varnier GC, Pilkington CA, Wedderburn LR. Juvenile dermatomyositis: novel treatment approaches and outcomes. Curr Opin Rheumatol. 2018;40:650-654.
Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, CARRA Juvenile Myositis subgroup. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J. 2017;15:71. doi:10.1186/s12969-017-0199-4
Wienke J, Pachman LM, Morgan GA, et al. Endothelial and inflammation biomarker profiles at diagnosis reflecting clinical heterogeneity and serving as a prognostic tool for treatment response in two independent cohorts of patients with juvenile dermatomyositis. Arthritis Rheum. 2020;72:1214-1226.
Hak AE, de Paepe B, de Bleecker JL, Tak P-P, de Visser M. Dermatomyositis and polymyositis: new treatment targets on the horizon. Neth J Med. 2011;69:410-421.